Document is current
Any future updates will be listed below
-
Authors
Girardis, M.
Bettex, D.
Bojan, M.
Demponeras, C.
Fruhwald, S.
Gál, J.
Groesdonk, H. V.
Guarracino, F.
Guerrero-Orriach, J. L.
Heringlake, M.
Herpain, A.
Heunks, L.
Jin, J.
Kindgen-Milles, D.
Mauriat, P.
Michels, G.
Psallida, V.
Rich, S.
Ricksten, S-E
Rudiger, A.
Siegemund, M.
Toller, W.
Treskatsch, S.
Župan, Ž.
Pollesello, P. http://orcid.org/0000-0001-6994-768X
- License Information
-
More Information
Article History
Received: 30 November 2021
Accepted: 13 December 2021
First Online: 24 January 2022
Declarations
:
: Not applicable.
: Not applicable.
: SR is an employee of Tenax Therapeutics which has the license to develop levosimendan in North America. PP is an employee of Orion Pharma, where levosimendan was discovered and developed as a treatment for AHF. In the last 5 years, MG, DB, HVG, FG, JLG-O, MH, AH, LMAH, HVG, DK-M, PM, GM, S-ER, AR, WT, ST, and ZZ have received honoraria for lectures and scientific advice and/or grants for investigator-initiated studies by Orion Pharma. MB, CD, SF, JG, VP, and MS do not declare any relevant conflicts of interest.
